Tyrosine kinase inhibitors

Details for Australian Patent Application No. 2004259734 (hide)

Owner Merck & Co., Inc.

Inventors Kim, Annette S.; Zhang, Xufang

Agent Spruson & Ferguson

Pub. Number AU-A-2004259734

PCT Pub. Number WO2005/009957

Priority 60/489,630 24.07.03 US

Filing date 20 July 2004

Wipo publication date 3 February 2005

International Classifications

C07D 207/333 (2006.01) Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom

A61K 31/40 (2006.01) - having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil

Event Publications

16 February 2006 PCT application entered the National Phase

  PCT publication WO2005/009957 Priority application(s): WO2005/009957

17 February 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004259736-Sulfonyldihydroimidazopyridinone compounds as 5-hydroxytryptamine-6 ligands

2004259731-RG1 antibodies and uses thereof